Cardiol Therapeutics Inc Class A (CRDL : TSX)
Common Stock
$1.51
CAD
+0.01 (0.66%)
Last updated: 2026-06-22
CRDL
Cardiol Therapeutics Inc Class A
WealthAwesomePerformance
1 Day
+0.66%
1 Week
+3.06%
1 Month
-16.76%
YTD
+11.40%
Key Statistics
Market Cap
$173.48M
52W High
$2.33
52W Low
$1.23
P/E Ratio
-
50 Day MA
$1.77
200 Day MA
$1.54
Beta
0.48
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/22/2026 | $1.50 | $1.52 | $1.50 | $1.51 | $1.51 | 12,801 |
| 6/19/2026 | $1.50 | $1.50 | $1.50 | $1.50 | $1.50 | 152 |
| 6/18/2026 | $1.49 | $1.53 | $1.48 | $1.50 | $1.50 | 28,147 |
| 6/17/2026 | $1.51 | $1.54 | $1.49 | $1.49 | $1.49 | 46,483 |
| 6/16/2026 | $1.49 | $1.49 | $1.43 | $1.47 | $1.47 | 44,598 |
| 6/15/2026 | $1.45 | $1.50 | $1.45 | $1.47 | $1.47 | 42,378 |
| 6/12/2026 | $1.52 | $1.52 | $1.46 | $1.46 | $1.46 | 26,798 |
| 6/11/2026 | $1.46 | $1.50 | $1.44 | $1.50 | $1.50 | 38,208 |
| 6/10/2026 | $1.56 | $1.56 | $1.45 | $1.49 | $1.49 | 65,515 |
| 6/9/2026 | $1.50 | $1.54 | $1.47 | $1.52 | $1.52 | 62,873 |
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 296.0% over the next 12 months.
Consensus
No RatingAvg. Target
C$6.00
+296.0% Upside
Current Price
C$1.51
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
37.8%
Annualized
90-Day Vol
59.7%
Annualized
Trend (90d)
-4.1%
Annualized drift
90d Mean
C$1.49
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.51 | C$1.32 โ C$1.72 |
| 60 trading days | C$1.50 | C$1.25 โ C$1.80 |
| 90 trading days | C$1.49 | C$1.19 โ C$1.87 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-35.57M
- Profit Margin
- 0.00%
- ROE (TTM)
- -173.96%
- EPS (Diluted)
- -0.39
- Book Value
- 0.22
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About CRDL
Articles Featuring CRDL.TO
Latest articles and analysis covering CRDL.TO
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A (CRDL.TO) has experienced a 2.31% increase in its stock price, driven by investor optimism linked to its clinical advancements and upcoming presentations.
Why Cardiol Therapeutics Inc Class A stock is gaining today
Cardiol Therapeutics Inc Class A (CRDL.TO) is gaining traction in the market, with a 0.67% increase in its stock price. The company's active involvement in industry events and clinical trials is boosting investor confidence.
Why Cardiol Therapeutics Inc Class A stock is rising today
Cardiol Therapeutics Inc Class A has seen its stock rise by 4.08%, closing at CA$1.53. This increase is attributed to positive developments in the company's clinical trial programs and strategic initiatives.
Why Cardiol Therapeutics Inc Class A stock is sliding today
Cardiol Therapeutics Inc Class A saw its stock slide 3.18% today, closing at CA$1.52. With no significant news driving the decline, investors are left to ponder the implications for the company's future.
